Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series

Código QR

Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series

Takayoshi Kiba,1 Nao Morii,2,3 Hirotoshi Takahashi,2 Shinji Ozaki,2 Misao Atsumi,4 Fumi Masumoto,4 Hiroyasu Yamashiro,2,31Division of Modern Medical Technology, Institute for Clinical Research, 2Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Cente...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kiba T, Morii N, Takahashi H, Ozaki S, Atsumi M, Masumoto F, Yamashiro H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/60b3f94bd12b4359b7e82fb7f3ad6e01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Victoria J Sinibaldi
Publicado: (2008)

Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial
por: Mitsuro Kanda, et al.
Publicado: (2021)

FEC Additive for Improved SEI Film and Electrochemical Performance of the Lithium Primary Battery
por: Xuan Zhou, et al.
Publicado: (2021)

Effects of FecB Mutation on Estrus, Ovulation, and Endocrine Characteristics in Small Tail Han Sheep
por: Xiangyu Wang, et al.
Publicado: (2021)

A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma
por: Kunnuru SKR, et al.
Publicado: (2020)

Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast
por: Yuki Usui, et al.
Publicado: (2021)

Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer
por: Sunghoon Joo, et al.
Publicado: (2021)

Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy
por: Jian Cui, et al.
Publicado: (2016)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung HT, et al.
Publicado: (2020)

The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
por: Elisabeth S Stovgaard, et al.
Publicado: (2021)

Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
por: Ana Julia Aguiar de Freitas, et al.
Publicado: (2021)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Lize Wang, et al.
Publicado: (2021)

Current neoadjuvant treatment options for HER2 positive breast cancer
por: Abdel-Razeq H, et al.
Publicado: (2011)

Gonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent manner.
por: Roberta M Moretti, et al.
Publicado: (2014)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Nina Radosevic-Robin, et al.
Publicado: (2021)

Characteristics and Risk Factors of Postoperative Complications in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy
por: SUN Chongyuan, et al.
Publicado: (2021)

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Jennifer L. Caswell-Jin, et al.
Publicado: (2019)

Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1
por: Yue Lu, et al.
Publicado: (2021)

Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
por: Minami Une, et al.
Publicado: (2021)

[2] Neoadjuvant intravesical chemotherapy to treat extended large non-muscle-invasive bladder cancer
por: Marco Raber, et al.
Publicado: (2018)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Alyssa Vito, et al.
Publicado: (2021)

NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo
por: Harada M, et al.
Publicado: (2012)

Intravoxel incoherent motion diffusion-weighted imaging for discriminating the pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
por: Wen Lu, et al.
Publicado: (2017)

Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis
por: Lihua Chen, et al.
Publicado: (2017)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
por: Jin Hong, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
por: Zeng-Jie Weng MM, et al.
Publicado: (2021)

Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy
por: Yushi Nagaki, et al.
Publicado: (2021)

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Jennifer L. Caswell-Jin, et al.
Publicado: (2019)

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
por: Sara A. Hurvitz, et al.
Publicado: (2020)

The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients
por: Sunao Tanaka, et al.
Publicado: (2017)

Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram
por: Hao Cui, et al.
Publicado: (2021)

Quantitative analysis of contrast enhanced spectral mammography grey value for early prediction of pathological response of breast cancer to neoadjuvant chemotherapy
por: Dong Xing, et al.
Publicado: (2021)

A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer
por: Yijun Li, et al.
Publicado: (2021)

Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies
por: Noori Koopaei M, et al.
Publicado: (2011)

Crohn's disease with pathological findings of a granulomatous lesion in the appendix
por: Naoya Sakamoto, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
por: M. Liontos, et al.
Publicado: (2021)

Environmental novelty exacerbates stress hormones and Aβ pathology in an Alzheimer’s model
por: Kimberley E. Stuart, et al.
Publicado: (2017)

How nanotechnology can enhance docetaxel therapy
por: Zhang L, et al.
Publicado: (2013)

Multifunctional gold nanorods and docetaxel-encapsulated liposomes for combined thermo- and chemotherapy
por: Hua H, et al.
Publicado: (2017)

Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
por: Peng Yang, et al.
Publicado: (2021)